Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study

Ashraf  Al Zaabi; Walter Javier  Mattarucco; Rocio Martina  Barriga; Hao-Chien  Wang; Dina V.  Diaz; Adel  Khattab; Manuel  Pacheco Gallego; Hisham  Farouk; David Price

Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study

Ashraf Al Zaabi
, Walter Javier Mattarucco
, Rocio Martina Barriga
, Hao-Chien Wang
, Dina V. Diaz
, Adel Khattab
, Manuel Pacheco Gallego
, Hisham Farouk
, David Price

National Taiwan University Hospital, Taipei
Lung Center of the Philippines
Ain Shams University
AstraZeneca
Zayed Military Hospital
CEPROSS (Centro Profesional San Salvador)
Hospital Angeles Chihuahua

Research output: Contribution to conference › Abstract › peer-review

7 Downloads (Pure)

Abstract

Introduction: The SABA use IN Asthma (SABINA) International cross-sectional study reported that 38% of 8,351 patients were prescribed =3 SABA canisters/year (overprescription).

Aim: This univariate post hoc analysis compares the sociodemographic and clinical characteristics of patients overprescribed SABA with those prescribed 1-2 canisters/year.

Methods: In patients aged =12 years with asthma, =3 physician consultations, and medical records containing data for =12 months before the study visit, multiple characteristics were compared using Chi-square or Kruskal-Wallis tests.

Results: Compared with patients prescribed 1-2 SABA canisters/year, a significantly higher percentage of those prescribed =3 SABA were obese (35.0% vs 29.2%) and ex-smokers (14.2% vs 10.9%), with a lower percentage receiving university or post-graduate education (30.7% vs 34.5%; Figure). A significantly higher percentage of patients prescribed =3 vs 1–2 SABA canisters/year were at Global Initiative for Asthma treatment Step 5 (18.9% vs 11.8%), classified with uncontrolled asthma (35.6% vs 21.2%) and reported 1 (24.6% vs 21.0%), 2 (14.2% vs 9.3%) or =3 severe asthma exacerbations (18.0% vs 11.0%).

Conclusion: The characteristics of patients overprescribed SABA will aid physicians in identifying and targeting those at risk of SABA overuse, thereby improving asthma outcomes globally.

Original language	English
Pages	2374
Publication status	Published - 5 Sept 2022
Event	European Respiratory Society (ERS) International Congress. - FIRA Barcelona Gran Via Congress Centre, Barcelona, Spain Duration: 4 Sept 2022 → 6 Sept 2022 https://www.ersnet.org/congress-and-events/congress/

Conference

Conference	European Respiratory Society (ERS) International Congress.
Abbreviated title	ERS International Congress 2022
Country/Territory	Spain
City	Barcelona
Period	4/09/22 → 6/09/22
Internet address	https://www.ersnet.org/congress-and-events/congress/

Funding

The study was designed and funded by Astrazeneca.

Funders
AstraZeneca

Access to Document

Zaabi_etal_ERS2022_Sociodemographic_And_Clinical_AAMAccepted author manuscript, 369 KBLicence: Unspecified

https://www.ers-education.org/lr/show-details/?idP=269195Licence: Unspecified

Cite this

Al Zaabi, A., Mattarucco, W. J., Barriga, R. M., Wang, H.-C., Diaz, D. V., Khattab, A., Pacheco Gallego, M., Farouk, H., & Price, D. (2022). Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study. 2374. Abstract from European Respiratory Society (ERS) International Congress., Barcelona, Spain. https://www.ers-education.org/lr/show-details/?idP=269195

Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study. / Al Zaabi, Ashraf ; Mattarucco, Walter Javier ; Barriga, Rocio Martina et al.
2022. 2374 Abstract from European Respiratory Society (ERS) International Congress., Barcelona, Spain.

Research output: Contribution to conference › Abstract › peer-review

Al Zaabi, A, Mattarucco, WJ, Barriga, RM, Wang, H-C, Diaz, DV, Khattab, A, Pacheco Gallego, M, Farouk, H & Price, D 2022, 'Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study', European Respiratory Society (ERS) International Congress., Barcelona, Spain, 4/09/22 - 6/09/22 pp. 2374. <https://www.ers-education.org/lr/show-details/?idP=269195>

@conference{e30c98a92fab421db7019d491df26865,

title = "Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study",

abstract = "Introduction: The SABA use IN Asthma (SABINA) International cross-sectional study reported that 38\% of 8,351 patients were prescribed =3 SABA canisters/year (overprescription). Aim: This univariate post hoc analysis compares the sociodemographic and clinical characteristics of patients overprescribed SABA with those prescribed 1-2 canisters/year. Methods: In patients aged =12 years with asthma, =3 physician consultations, and medical records containing data for =12 months before the study visit, multiple characteristics were compared using Chi-square or Kruskal-Wallis tests. Results: Compared with patients prescribed 1-2 SABA canisters/year, a significantly higher percentage of those prescribed =3 SABA were obese (35.0\% vs 29.2\%) and ex-smokers (14.2\% vs 10.9\%), with a lower percentage receiving university or post-graduate education (30.7\% vs 34.5\%; Figure). A significantly higher percentage of patients prescribed =3 vs 1{\textendash}2 SABA canisters/year were at Global Initiative for Asthma treatment Step 5 (18.9\% vs 11.8\%), classified with uncontrolled asthma (35.6\% vs 21.2\%) and reported 1 (24.6\% vs 21.0\%), 2 (14.2\% vs 9.3\%) or =3 severe asthma exacerbations (18.0\% vs 11.0\%). Conclusion: The characteristics of patients overprescribed SABA will aid physicians in identifying and targeting those at risk of SABA overuse, thereby improving asthma outcomes globally.",

author = "\{Al Zaabi\}, Ashraf and Mattarucco, \{Walter Javier\} and Barriga, \{Rocio Martina\} and Hao-Chien Wang and Diaz, \{Dina V.\} and Adel Khattab and \{Pacheco Gallego\}, Manuel and Hisham Farouk and David Price",

year = "2022",

month = sep,

day = "5",

language = "English",

pages = "2374",

note = "European Respiratory Society (ERS) International Congress., ERS International Congress 2022 ; Conference date: 04-09-2022 Through 06-09-2022",

url = "https://www.ersnet.org/congress-and-events/congress/",

}

TY - CONF

T1 - Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study

AU - Al Zaabi, Ashraf

AU - Mattarucco, Walter Javier

AU - Barriga, Rocio Martina

AU - Wang, Hao-Chien

AU - Diaz, Dina V.

AU - Khattab, Adel

AU - Pacheco Gallego, Manuel

AU - Farouk, Hisham

AU - Price, David

PY - 2022/9/5

Y1 - 2022/9/5

N2 - Introduction: The SABA use IN Asthma (SABINA) International cross-sectional study reported that 38% of 8,351 patients were prescribed =3 SABA canisters/year (overprescription). Aim: This univariate post hoc analysis compares the sociodemographic and clinical characteristics of patients overprescribed SABA with those prescribed 1-2 canisters/year. Methods: In patients aged =12 years with asthma, =3 physician consultations, and medical records containing data for =12 months before the study visit, multiple characteristics were compared using Chi-square or Kruskal-Wallis tests. Results: Compared with patients prescribed 1-2 SABA canisters/year, a significantly higher percentage of those prescribed =3 SABA were obese (35.0% vs 29.2%) and ex-smokers (14.2% vs 10.9%), with a lower percentage receiving university or post-graduate education (30.7% vs 34.5%; Figure). A significantly higher percentage of patients prescribed =3 vs 1–2 SABA canisters/year were at Global Initiative for Asthma treatment Step 5 (18.9% vs 11.8%), classified with uncontrolled asthma (35.6% vs 21.2%) and reported 1 (24.6% vs 21.0%), 2 (14.2% vs 9.3%) or =3 severe asthma exacerbations (18.0% vs 11.0%). Conclusion: The characteristics of patients overprescribed SABA will aid physicians in identifying and targeting those at risk of SABA overuse, thereby improving asthma outcomes globally.

AB - Introduction: The SABA use IN Asthma (SABINA) International cross-sectional study reported that 38% of 8,351 patients were prescribed =3 SABA canisters/year (overprescription). Aim: This univariate post hoc analysis compares the sociodemographic and clinical characteristics of patients overprescribed SABA with those prescribed 1-2 canisters/year. Methods: In patients aged =12 years with asthma, =3 physician consultations, and medical records containing data for =12 months before the study visit, multiple characteristics were compared using Chi-square or Kruskal-Wallis tests. Results: Compared with patients prescribed 1-2 SABA canisters/year, a significantly higher percentage of those prescribed =3 SABA were obese (35.0% vs 29.2%) and ex-smokers (14.2% vs 10.9%), with a lower percentage receiving university or post-graduate education (30.7% vs 34.5%; Figure). A significantly higher percentage of patients prescribed =3 vs 1–2 SABA canisters/year were at Global Initiative for Asthma treatment Step 5 (18.9% vs 11.8%), classified with uncontrolled asthma (35.6% vs 21.2%) and reported 1 (24.6% vs 21.0%), 2 (14.2% vs 9.3%) or =3 severe asthma exacerbations (18.0% vs 11.0%). Conclusion: The characteristics of patients overprescribed SABA will aid physicians in identifying and targeting those at risk of SABA overuse, thereby improving asthma outcomes globally.

M3 - Abstract

SP - 2374

T2 - European Respiratory Society (ERS) International Congress.

Y2 - 4 September 2022 through 6 September 2022

ER -

Sociodemographic and clinical characteristics of patients with asthma who were prescribed ≥3 SABA canisters/year in the SABINA International study

Abstract

Conference

Funding

Access to Document

Fingerprint

Cite this